INITIAL EVALUATION OF THE EFFICACY AND SAFETY OF CDK4/6 INHIBITORS IN PATIENTS WITH METASTATIC BREAST CANCER HR+HER2- AT CHO RAY HOSPITAL
Main Article Content
Abstract
Objectives: To evaluate the efficacy and toxicity of the CDK4/6 inhibitor Ribociclib combined with endocrine therapy (ET) in metastatic breast cancer patients with hormone receptor-positive (HR+) and HER2 negative (HER2-). Methods: A retrospective study of 25 cases treated with the CDK4/6 inhibitor Ribociclib combined with an aromatase inhibitor (AI) or fulvestrant at Cho Ray Hospital from December 1, 2021 to February 28, 2024. Results: The average age was 62.0 years old. Common metastatic features are visceral metastases (liver, lungs), brain metastases, bone metastases only, and other metastases (lymph nodes, chest wall) with rates of 55%, 14%, 24%, and 45%, respectively. Among 25 patients treated with Ribociclib + endocrine therapy, 18 patients were treated with AI (72%), and 7 patients were treated with fulvestrant (28%). The proportion of patients receiving first-line treatment is 72%, and the second-line is 28%. Median progression-free survival was 20.0 months. The rate of disease progression at 6, 12, 18 and 24 months was 79%, 58%, 53% and 42%, respectively. The most common adverse event was neutropenia (69%), of which the rates of level 3 and 4 leukopenia were 24% and 14%, respectively, with no cases of fever recorded. Conclusion: It has shown high efficacy and low toxicity in CDK4/6i Ribociclib plus endocrine therapy.
Article Details
Keywords
advanced breast cancer, endocrine therapy, HER2-negative, hormone receptor-positive, Ribociclib.
References
2. Đức, Phan Thị Hồng, Bước đầu đánh giá hiệu quả và tính an toàn của thuốc ức chế CDK4/6 trên bệnh nhân ung thư vú di căn HR+ HER2- tại bệnh viện Ung Bướu TP. HCM. Tạp chí Y học Việt Nam, 2022. 520: p. 302-314.
3. De Laurentiis, M., et al., Full population results from the core phase of CompLEEment-1, a phase 3b study of Ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population. Breast Cancer Res Treat, 2021. 189(3): p. 689-699.
4. Hortobagyi, Gabriel N., et al., Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. New England Journal of Medicine, 2022. 386(10): p. 942-950.
5. Im, Seock-Ah, et al., Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. New England Journal of Medicine, 2019. 381(4): p. 307-316.
6. Johnston, S., et al., MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer, 2019. 5: p. 5.
7. Lu, Yen-Shen, et al., Final results of RIGHT Choice: Ribociclib plus endocrine therapy vs combination chemotherapy in premenopausal women with clinically aggressive HR+/HER2− advanced breast cancer. Journal of Clinical Oncology. 0(0): p. JCO.24.00144.
8. Lüftner, Diana, et al., Real-world efficacy of Ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Results of fourth interim analysis (IA) from RIBANNA. Journal of Clinical Oncology, 2022. 40(16_suppl): p. 1065-1065.
9. Slamon, Dennis J., et al., Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. New England Journal of Medicine, 2020. 382(6): p. 514-524.